Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;29:205-209

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granger, J.
Right arrow Articles by Kassab, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granger, J.
Right arrow Articles by Kassab, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
*SODIUM

(Hypertension. 1997;29:205.)
© 1997 American Heart Association, Inc.


Arthur C. Corcoran Memorial Lecture

Role of Nitric Oxide in Modulating the Long-term Renal and Hypertensive Actions of Norepinephrine

Joey Granger; Christine Schnackenberg; Jackie Novak; Brett Tucker; Todd Miller; Stephen Morgan; Salah Kassab

From the Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Miss.

Correspondence to Joey P. Granger, PhD, Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216-4505. E-mail JPG{at}fiona.umsmed.edu

We have previously reported that nitric oxide (NO) plays an important role in protecting the renal vasculature from acute norepinephrine-induced vasoconstriction. The purpose of this study was to determine the importance of this interaction between NO and norepinephrine in long-term control of renal hemodynamics and arterial pressure. To achieve this goal, we examined the effects of an intrarenal infusion of norepinephrine (NE) (0.1 µg·kg-1·min-1) for 7 days in conscious, chronically instrumented control dogs and in dogs pretreated with a synthesis inhibitor, L-NAME (3 µg·kg-1·min-1 intrarenally). Both groups of dogs also received captopril (15 µg·kg-1·min-1) plus angiotensin II intravenously to clamp the renin-angiotensin system throughout the protocol. In control dogs (n=6), intrarenal infusion of NE decreased renal plasma flow by 9% (134±10 to 122±14 mL/min) and glomerular filtration rate by 16% (49±4 to 41±5 mL/min) while having no effect on mean arterial pressure (100±3 to 98±4 mm Hg). In marked contrast, in dogs pretreated with intrarenal L-NAME (n=9), NE decreased renal plasma flow by 37% (129±8 to 81±16 mL/min) and glomerular filtration rate by 32% (47±3 to 32±5 mL/min) while increasing mean arterial pressure from 104±5 to 113±6 mm Hg. The results of this study demonstrate that NO plays an important role in modulating the long-term actions of NE on renal function and arterial pressure.


Key Words: endothelial factors • kidney • renal hemodynamics • arterial pressure

Abbreviations: GFR = glomerular filtration rate • L-NAME = N-nitro-L-arginine methyl ester • MAP = mean arterial pressure • RPF = renal plasma flow • RVR = renal vascular resistance




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. Lopez, M. T. Llinas, F. Roig, and F. J. Salazar
Role of nitric oxide and cyclooxygenase-2 in regulating the renal hemodynamic response to norepinephrine
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R488 - R493.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. T. Llinas, R. Lopez, F. Rodriguez, F. Roig, and F. J. Salazar
Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine
Am J Physiol Renal Physiol, November 1, 2001; 281(5): F975 - F982.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. N. Muscara, W. McKnight, F. Lovren, C. R. Triggle, G. Cirino, and J. L. Wallace
Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats
Am J Physiol Heart Circ Physiol, August 1, 2000; 279(2): H528 - H535.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Montanari, E. Tateo, E. Fasoli, A. Donatini, B. Cimolato, P. Perinotto, and P. Dall'Aglio
Dopamine-2 Receptor Blockade Potentiates the Renal Effects of Nitric Oxide Inhibition in Humans
Hypertension, January 1, 1998; 31(1): 277 - 282.
[Abstract] [Full Text] [PDF]